---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000046"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-08-28T23:59:59+00:00"
generated_at: "2026-06-11T02:54:14.744203+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer

## Summary
- Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.
- 540 patients enrolled; trial designed for platinum-resistant ovarian cancer.
- TTFields therapy well-tolerated without added systemic toxicities.
- Exploratory subgroup suggests potential survival benefit in patients with only one prior therapy line.
- Full data analysis ongoing; results to be shared with scientific community.

## SEC filing metadata
- accession: 0001645113-23-000046
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/0001645113-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000046/nvcr-20230828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000046
- JSON: https://secwatch.observer/filing/0001645113-23-000046.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.